Astellas Signs Option and License Deal With Audax for Cancer Drug Worth Up to US$ 1.34 Billion
Bitget2026/10/27 23:30- Astellas Pharma entered an exclusive option agreement with Audax Biosciences for worldwide rights to develop, manufacture and commercialize cancer drug DAX-044.
- The deal totals up to US$1.34 billion excluding royalties, including US$285 million in upfront and potential option exercise payments.
- Audax could receive up to US$1.05 billion in development and commercial milestones, alongside tiered double-digit royalties on worldwide net sales if approved.
- Audax will fund development into Phase 1, expected to begin in 2027; exercising the option transfers global responsibility to its partner.
- The agreement gives Audax the option to co-fund and co-promote DAX-044 in Australia and New Zealand.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
